DT Dianthus Therapeutics, Inc. /DE/ Stock: price and directors' dealings · United States · SEC (Form 4)Source id SEC:dianthus-therapeutics-inc-de-70a405 US · SEC (Form 4) Mcap US$5.9B Track the Dianthus Therapeutics, Inc. /DE/ share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €5.9bn. The latest transaction was filed on 3 September 2026 (Levée d'options). Among the most active insiders: Savitz Ryan. Every trade is openly available.
Analyst consensus: bullish or bearish? Analysts rate Dianthus Therapeutics, Inc. /DE/ Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
All Executives77 Thresholds0 Prospectus0 Other0
Declarations 77 total
◇ EVP, Head of R&D · Executives · 1 Sept 2026
7,500 shares @ US$17.88 Common Stock SEC:0001992260-26-000009:0
◇ EVP, Head of R&D · Executives · 1 Sept 2026
6,249 shares @ US$21.77 Common Stock SEC:0001992260-26-000009:1
◇ EVP, Head of R&D · Executives · 1 Sept 2026
9,375 shares @ US$22.07 Common Stock SEC:0001992260-26-000009:2
▼ EVP, Head of R&D · Executives · 1 Sept 2026
2,600 shares @ US$105.19 Common Stock SEC:0001992260-26-000009:3
▼ EVP, Head of R&D · Executives · 1 Sept 2026
7,215 shares @ US$106.25 Common Stock SEC:0001992260-26-000009:4
▼ EVP, Head of R&D · Executives · 1 Sept 2026
13,309 shares @ US$106.74 Common Stock SEC:0001992260-26-000009:5
◇ Director · Executives · 19 Aug 2026
2,778 shares @ US$18.36 0.0008% mcap 3.8% of flow Common Stock SEC:0001688199-26-000006:0
▼ Director · Executives · 19 Aug 2026
2,778 shares @ US$117.55 0.0051% mcap 24.0% of flow Common Stock SEC:0001688199-26-000006:1
◇ SVP, General Counsel and Sec. · Executives · 13 Aug 2026
15,000 shares @ US$18.17 0.0044% mcap 9.6% of flow Common Stock SEC:0001778623-26-000009:0
▼ Director · Executives · 10 Aug 2026
70 shares @ US$107.11 0.0001% mcap 0.8% of flow Common Stock SEC:0001688199-26-000004:1
▼ Director · Executives · 10 Aug 2026
737 shares @ US$108.17 0.0013% mcap 8.1% of flow Common Stock SEC:0001688199-26-000004:2
▼ Director · Executives · 10 Aug 2026
831 shares @ US$108.95 0.0015% mcap 9.2% of flow Common Stock SEC:0001688199-26-000004:3
▼ Director · Executives · 10 Aug 2026
272 shares @ US$109.96 0.0005% mcap 3.1% of flow Common Stock SEC:0001688199-26-000004:4
▼ Director · Executives · 10 Aug 2026
470 shares @ US$111.05 0.0009% mcap 5.3% of flow Common Stock SEC:0001688199-26-000004:5
▼ Director · Executives · 10 Aug 2026
397 shares @ US$111.77 0.0007% mcap 4.5% of flow Common Stock SEC:0001688199-26-000004:6
◇ SVP, General Counsel and Sec. · Executives · 7 Aug 2026
3,833 shares @ US$17.88 0.0011% mcap 2.7% of flow Common Stock SEC:0001778623-26-000007:0
▼ SVP, General Counsel and Sec. · Executives · 7 Aug 2026
3,217 shares @ US$110.61 0.0058% mcap 13.9% of flow Common Stock SEC:0001778623-26-000007:1
▼ SVP, General Counsel and Sec. · Executives · 10 Aug 2026
16,167 shares @ US$110.38 0.029% mcap 69.5% of flow Common Stock SEC:0001778623-26-000007:4
◇ Director · Executives · 10 Aug 2026
6,500 shares @ US$11.20 0.0012% mcap 7.7% of flow Common Stock SEC:0001779934-26-000004:1
▼ Director · Executives · 10 Aug 2026
1,450 shares @ US$107.58 0.0025% mcap 16.6% of flow Common Stock SEC:0001779934-26-000004:2
▼ Director · Executives · 10 Aug 2026
2,800 shares @ US$108.38 0.0050% mcap 32.2% of flow Common Stock SEC:0001779934-26-000004:3
▼ Director · Executives · 10 Aug 2026
1,000 shares @ US$110.64 0.0018% mcap 11.7% of flow Common Stock SEC:0001779934-26-000004:5
◇ Director · Executives · 10 Aug 2026
1,250 shares @ US$19.36 0.0004% mcap 2.6% of flow Common Stock SEC:0001779934-26-000004:0
▼ SVP, General Counsel and Sec. · Executives · 7 Aug 2026
616 shares @ US$111.18 0.0011% mcap 2.7% of flow Common Stock SEC:0001778623-26-000007:2
◇ Director · Executives · 10 Aug 2026
2,777 shares @ US$18.36 0.0008% mcap 5.2% of flow Common Stock SEC:0001688199-26-000004:0
25 of 77 declarations
Load more (52 remaining) 关于 Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics, Inc. 是一家生物制药公司，专注于开发治疗自身免疫性疾病的创新疗法。该公司在纳斯达克上市，股票代码为 DE。